Abstract
Cirrhosis, ascites and renal impairment are associated with high morbidity and mortality. The hepatorenal syndrome (HRS) is a type of renal failure that affects patients with cirrhosis and ascites. This paper provides an update on evidence-based interventions in HRS. A number of factors can precipitate HRS. The monitoring, prevention, early detection, and correct treatment of these are essential. Terlipressin combined with albumin is the first-line treatment of type 1 HRS. In type 2 HRS with refractory ascites, liver transplantation and TIPS should be considered.
MeSH terms
-
Albumins / therapeutic use
-
Ascites / diagnosis
-
Ascites / etiology
-
Ascites / prevention & control
-
Ascites / therapy
-
Drug Therapy, Combination
-
Evidence-Based Medicine
-
Hepatorenal Syndrome* / diagnosis
-
Hepatorenal Syndrome* / etiology
-
Hepatorenal Syndrome* / prevention & control
-
Hepatorenal Syndrome* / therapy
-
Humans
-
Kidney / drug effects
-
Liver Cirrhosis / complications
-
Liver Cirrhosis / therapy
-
Liver Transplantation
-
Lypressin / adverse effects
-
Lypressin / analogs & derivatives
-
Lypressin / therapeutic use
-
Portasystemic Shunt, Transjugular Intrahepatic
-
Terlipressin
-
Vasoconstrictor Agents / adverse effects
-
Vasoconstrictor Agents / therapeutic use
Substances
-
Albumins
-
Vasoconstrictor Agents
-
Lypressin
-
Terlipressin